STACK · ↗ Additive ladder · 3 tiers
Recovery & Repair.
BPC-157 + TB-500 — scar-free repair, locally and systemically.
Hook facts
The science, in one line each.
BPC-157 is derived from a protein naturally present in human gastric juice — the same fluid that digests food — and it's so stable in stomach acid that it remains intact and active when swallowed, which is why it's the rare peptide that actually works orally, not just by injection.
TB-500 is based on Thymosin Beta-4, a peptide so fundamental to cellular life that it's found in virtually every cell in the human body — and when researchers knock out its gene in mice, wounds that should heal in days instead never close at all.
The combination is nicknamed the 'Wolverine Stack' in biohacker and athletic communities — named after Marvel's famously self-healing mutant — because the two peptides together cover so many independent repair pathways that users describe injury timelines that seem implausibly fast compared to conventional recovery.
When to skip it
Read this first.
Anyone with active cancer or a history of hormone-sensitive tumours should avoid this stack until cleared by their physician. It's also not the right fit for people looking for passive recovery — these peptides amplify your body's repair signals, but they work best when paired with movement, rehab, and load-appropriate training.
Always cleared with your concierge before protocol start.
Why this works
The strongest evidence.
In a controlled animal study published in the Journal of Physiology–Pharmacology (Sikiric et al., 2009), BPC-157 accelerated healing of transected Achilles tendon and medial collateral ligament without the formation of scar tissue — a critical distinction, since scar tissue is weaker and more prone to re-injury than native tendon. TB-500's mechanism is distinct: as a synthetic fragment of Thymosin Beta-4, it upregulates G-actin — the monomer form of actin involved in cell migration — which drives stem-cell mobilisation and accelerates repair across tissue types systemically, not just at the injection site. The clean, functional repair observed preclinically is consistent with what clinicians report in post-surgical recovery protocols combining BPC-157 with TB-500.
Additive ladder
Choose your tier.
Each tier builds on the last. Start where you are — add depth as your goals evolve.
Healing Starter
BPC-157 drives the local repair signal — angiogenesis, growth factor activation, mucosal healing. It's the most versatile single peptide in the recovery category. Mechanistically, BPC-157 promotes new blood vessel formation at the injury site and activates the growth factor pathways that initiate tissue remodelling. For many users it's all they need: a focused, lower-cost entry that works across gut, tendon, and nerve applications alike. If you're dealing with a single injury site or want to test your response to peptides before adding TB-500, start here.
Who it's for
First-time peptide users, or anyone with GI-driven inflammation, gut-lining issues, or a single localised injury. BPC-157 alone is the cleanest, lowest-commitment entry point — no injection frequency concerns about TB-500.
What to expect
Reduced localised inflammation and early signs of tissue repair within 7–14 days. Gut applications typically show meaningful symptom relief (less bloating, improved motility) by the end of week two.
The Wolverine Stack
BPC-157 handles local repair at the injury site; TB-500 handles systemic mobilisation — upregulating actin and driving stem cells toward damaged tissue throughout the body. These are complementary stages of the healing cascade, and running both from day one compounds results in a way that sequencing them doesn't. Most users inject them separately, which preserves dose flexibility. If you'd rather reduce needle-sticks, the tb500-bpc157-combo vial delivers both in a single injection — the trade-off is fixed dosing ratios. Either route covers the full Wolverine Stack mechanism.
Who it's for
Athletes and active adults with tendon or ligament injuries who want the complete 'Wolverine Stack'. The gold-standard protocol for anyone training through injury or post-surgical recovery. Includes the option of the pre-mixed tb500-bpc157-combo vial for users managing injection fatigue.
What to expect
Significant pain reduction and mobility improvement by week 4. TB-500's systemic stem-cell mobilisation adds whole-body anti-inflammatory depth that BPC-157 alone can't match. Most tendon and ligament cases see functional restoration by week 8–12.
Topical Repair
+ sits on top of any tier above
The Standard stack gets a topical layer for users with surface or mucosal involvement. BPC-spray delivers BPC-157 directly to the tissues it touches — gut mucosa, oral cavity, or respiratory tract — through a route that injectable BPC-157 can't always replicate with the same local concentration. It's not a replacement for systemic injection; absorbed levels differ. Think of it as additive: injections drive systemic and near-site repair, the spray targets mucosal surfaces where direct application changes the pharmacology. For post-procedure oral wounds, GI lining repair, or chronic respiratory inflammation, this layer earns its place.
Who it's for
Users with skin, wound, or mucosal involvement — post-procedure recovery, surgical scars, chronic GI inflammation, or respiratory mucosal issues — who want a topical layer alongside systemic injections.
What to expect
Faster surface-level wound closure and reduced scar formation by week 4–6. The BPC spray acts directly on mucosal tissue it contacts — gut lining, oral cavity, airway — at concentrations that injected BPC-157 may not reach in those specific compartments.
The science
Peer-reviewed findings.
Key research findings from the compounds in this stack.
BPC-157 significantly upregulates growth hormone receptor expression in tendon fibroblasts in a dose- and time-dependent manner, explaining its consistent ability to accelerate tendon-to-bone healing across multiple injury models
SOURCE · PMC6271067 — Frontiers in Pharmacology / PubMed Central; Chang et al., tendon outgrowth studies
In clinical trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736), BPC-157 demonstrated safety in human subjects with no dose-limiting toxicity — the LD1 was never achieved even at high doses, making it one of the most safety-studied experimental peptides
SOURCE · ResearchGate / Sikiric et al.; PubMed 17713731
A Phase 1 safety study in healthy volunteers found recombinant Thymosin Beta-4 was well tolerated at both single and multiple intravenous doses, with no dose-limiting toxicities or serious adverse events reported
SOURCE · Wang et al., 2021 — Phase 1 clinical safety trial (cited in Dr. Jeffrey Peng MD clinical review, 2024)
In a clinically relevant porcine model of myocardial infarction, Tβ4 mediated significant cardioprotective effects via endothelial progenitor cells, demonstrating tissue-repair activity well beyond musculoskeletal applications
SOURCE · Peptide Biologix clinical monograph; translational porcine cardiac study
Both BPC-157 and TB-500 demonstrate convergent effects on angiogenesis promotion and inflammatory modulation while maintaining distinct molecular targets — a preclinical rationale for synergistic therapeutic applications in regenerative medicine contexts
SOURCE · GlobalRPh Clinical Review: BPC-157 and TB-500 Background, Indications, Efficacy, and Safety (2025)
BPC-157 shows stronger activity in gastrointestinal and connective tissue repair models, while Thymosin Beta-4 (TB-500's parent compound) demonstrates distinct cardiac and immunological effects — the stack covers tissue types that neither covers alone
SOURCE · Newtropin.com Comparative Clinical Overview; Raw Amino comparative research review
Protocol
How to run it.
Frequency
Daily subcutaneous injections, 5 days on / 2 days off (Monday–Friday). BPC-157: 250–500 mcg once daily near the injury site, or systemic for gut/nerve applications. TB-500: 2–5 mg split across 2–3 injections per week during loading, reducing to 2 mg once weekly in maintenance. If using the pre-mixed TB-500/BPC-157 combo vial, follow the same per-injection frequency — you're reducing needle-sticks, not changing the protocol.
Duration
4–8 weeks for acute injuries; 8–12 weeks for chronic tendinopathy or post-surgical cases. Loading phase (Weeks 1–4) uses higher TB-500 frequency; maintenance phase (Weeks 5–8+) scales back.
Timing
BPC-157 can be injected at any time — morning or post-workout both work. TB-500 is systemic, so timing is less critical; many prefer mornings. Inject BPC-157 close to the injury site for localized repair, or subcutaneously in the abdomen for systemic/gut effects.
Cycling
Run the full protocol for 8–12 weeks, then take 4 weeks off before reassessing. For chronic or recurring injuries, a second cycle can follow after the break. Avoid open-ended continuous use until more long-term human data is available.
Who it's for
Your profile.
Athletes, weekend warriors, and active adults dealing with soft-tissue injuries that won't fully heal — think nagging tendon issues, ligament sprains, muscle tears, or post-surgical recovery. People who have gone through physical therapy without getting back to full function, or who keep re-injuring the same spot, tend to see the strongest results. It's also well-suited for anyone with chronic inflammation, joint degeneration, or gut-driven inflammation that blunts overall recovery. If you're the type of person who trains through discomfort and just wants your body to keep up, this stack was built for you.
Timeline
What to expect.
- 01
Week 1–2
Pain reduction and improved mobility are usually the first signals — most users notice meaningful changes within 7–10 days when dosing is consistent. Reduced stiffness in the morning, less post-workout soreness, and a general sense that the injured area feels 'less angry.' Don't expect structural repair yet — this is the inflammatory phase quieting down.
- 02
Week 6
Functional improvement becomes more pronounced. Tendons and ligaments that were previously limiting range of motion tend to feel noticeably more resilient. Athletes often find they can train at higher loads without the same pain response. Gut-healing applications typically show clear improvement in digestive symptoms by this point.
- 03
Week 12
For chronic injuries or post-surgical cases, week 12 is often where the real payoff lands — tissue quality improves, scar formation is minimised, and structural integrity returns. Many users report returning to full training loads or activities they had written off. Sustained reduction in baseline inflammation is common in cases where systemic use was the goal.
Stacking notes
How this combines.
BPC-157 and TB-500 are genuinely complementary rather than redundant — BPC-157 drives localised repair through angiogenesis and growth factor signalling at the injury site, while TB-500 works systemically by upregulating actin, mobilising stem cells, and reducing whole-body inflammatory load. Run them together from day one rather than sequencing them. The combo is sometimes called the 'Wolverine Stack' in clinical wellness circles for exactly this reason. The tb500-bpc157-combo vial is a pre-mixed formulation containing both peptides. For users prioritising compliance or managing injection fatigue, a single vial halves the needle count per session. The trade-off: you lose the ability to adjust each peptide's dose independently. If your protocol calls for higher BPC-157 relative to TB-500 — common in gut-focused or nerve-repair cases — separate vials give you that flexibility. Important: the community guidance (and clinical sources) is clear that you should not mix BPC-157 and TB-500 yourself in a single syringe — use the purpose-formulated combo vial or keep them separate. BPC-spray (oral/topical spray) works through a different delivery route entirely: BPC-157 applied to mucosal surfaces — gut lining, oral cavity, respiratory tract — can act locally on tissue it contacts directly. This is not a substitute for systemic injection; absorbed concentrations differ. It's additive for users with GI mucosal involvement or surface wounds where topical concentration matters. Note: TB-500 is on the WADA prohibited list — competitive athletes subject to WADA testing should not use it during sanctioned competition periods. BPC-157 is currently not on the WADA list.